Ticker brief
STLN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
3
crowd 14d
+0.59
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-19 · now +0.80 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @LogicalThesis | A | +2.21 | 2 | +0.28 |
| @CorneliaLake | A | +0.18 | 2 | +0.76 |
| @BlueDuckCap | A | +1.95 | 1 | +0.80 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-19 | @BlueDuckCap | +0.80 | Calls the oncology immunotherapy readthrough strongly bullish for STLN | · | tweet ↗ |
| 2026-08-17 | @LogicalThesis | +0.30 | Reports insider purchases at KURA, STIM and STLN, led by a $1.1M CEO buy. | · | tweet ↗ |
| 2026-08-17 | @CorneliaLake | +0.80 | Starling launched Nexus, with the author arguing it expands compliance, attachment and revenue potential. | · | tweet ↗ |
| 2026-08-15 | @CorneliaLake | +0.72 | Argues STLN is transforming into a specialty-pharmacy business with improved FCF conversion. | · | tweet ↗ |
| 2026-08-15 | @LogicalThesis | +0.25 | Suggests STLN as a name worth examining in the referenced category. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.